WATERTOWN, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and […]
– Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications – – […]
YONKERS, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and […]